

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Synthesis and preliminary evaluation of model compounds targeting the NLRP3 inflammasome pathways

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/152704> since

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Synthesis and preliminary evaluation of model compounds targeting the NLRP3 inflammasome pathways


Davide Garella, Mattia Cocco, Antonella Di Stilo, Gianluca Miglio, Massimo Collino, Roberto Fantozzi, Massimo Bertinaria

Dipartimento di Scienza e Tecnologia del Farmaco. Università degli Studi di Torino. Via P. Giuria 9, 10125 Torino – Italia

davide.garella@unito.it

Introduction

Inflammasomes have recently emerged as key mediators of inflammation and immunity. Four inflammasome complexes have been described to date. The most intensely studied is the NLRP3 inflammasome formed by the nucleotide-binding domain leucine-rich repeat family member NLRP3 and the adapter protein ASC, its assembling is triggered by a diverse series of endogenous and exogenous stimuli.¹ (figure 1).



NLRP3 assembly leads to caspase-1 activation which causes the maturation and secretion of the pro-inflammatory cytokines IL-1β and IL-18.


Fig. 1. Model of inflammasome activation.

Coordination of a manifold series of signals culminates in the activation of the inflammasome.

A series of autosomal and dominant or *de novo* mutations of *nlrp3* lead to auto-inflammatory syndromes known as CAPS (cryopyrin-associated periodic syndromes) which are characterized by high levels of IL-1β release and associated sterile systemic inflammation. The onset of chronic inflammation has also been linked to a wide range of metabolic disorders, such as type 2 diabetes, atherosclerosis, and Alzheimer's disease.²

Design of inhibitors of NLRP3-related pathways

Few small molecules inhibitors of NLRP3 inflammasome-related effects have been described, among them **parthenolide**, **Bay 11-7082** and **bromoxone** are the most studied.



These molecules share the ability to behave as **Michael acceptors**. Although Michael acceptors are traditionally shunned in modern drug discovery, many biologically relevant and druggable pathways are targeted by thiol-reactive compounds.³

To explore the use of **Michael acceptors** as pharmaco-chemical tools modulating inflammatory pathways we designed some model compounds (figure 2).






Fig. 2. General structure of designed Michael acceptors

Synthesis

Designed compounds were synthesized via the Morita-Baylis-Hillman (MBH) reaction (scheme 1).



Optimisation of reaction conditions



Solvent	catalyst	Time (d)	Yield ^a	Solvent	catalyst	Time (d)	Yield ^a			
CHCl ₃	Et ₃ N	7	-	CH ₃ CN/H ₂ O	Et ₃ N	7	-			
CHCl ₃	DMAP	19	54 %	CH ₃ CN/H ₂ O	DMAP	5	42 %			
CHCl ₃	DBU	12	25 %	CH ₃ CN/H ₂ O	DBU	20	trace			
CHCl ₃	Im	7	-	CH ₃ CN/H ₂ O	Im	20	< 2%			
CHCl ₃	DABCO	7	-	CH ₃ CN/H ₂ O	DABCO	7	67 %			
CHCl ₃	PPh ₃	7	c	CH ₃ CN/H ₂ O	PPh ₃	4	c			
CHCl ₃	TMEDA	7	-	CH ₃ CN/H ₂ O	TMEDA	20	trace			
Tab. 1 a) Isolated yields; b) reaction run on 10 mmol scale; c) complex mixture; d) run at 80 °C. Solvents: dioxane/H ₂ O (1/1); CH ₃ CN/H ₂ O (9/1); THF/MeOH/H ₂ O (1/1/2)				Dioxane/H ₂ O				DABCO	20	-
				THF/MeOH/H ₂ O				DABCO	4	44 %
				CH ₃ CN/H ₂ O				DABCO	7	65 % ^b
				CH ₃ CN/H ₂ O				DABCO	2 ^d	40 % ^b


✓ Use of polar protic medium is preferred

✓ Use of DABCO or DMAP gives best results

✓ Long reaction times are required

✓ Scale-up can be effectively obtained


The synthesis of E- N- X- series of compounds was obtained through reaction of ethylacrylate or acrylonitrile with different aldehydes.



	E compounds			Reaction conditions			N compounds			Reaction conditions			
	R1	R2	R3	solv	catalyst	yield	R1	R2	R3	solv	catalyst	yield	
1E	-H	-H	-H	B	DABCO	45%	1N	-H	-H	-H	D	DABCO	69 %
2E	-H	2-NO ₂	-H	A	DABCO	60 %	2N	-H	2-NO ₂	-H	A	DABCO	44 %
3E	-H	2-F	-H	A	DABCO	66 %	4N	-H	2-Cl	-H	D	DABCO	quant
4E	-H	2-Cl	-H	B	DABCO	67 %	5N	-H	2-Br	-H	D	DABCO	quant
5E	-H	2-Br	-H	B	DABCO	quant	7N	-H	2-Cl	4-Cl	D	DABCO	37 %
6E	-H	4-Cl	-H	B	DMAP	38 %	8N	-H	2-Cl	6-Cl	D	DABCO	21 %
7E	-H	2-Cl	4-Cl	B	DMAP	58 %	X compounds			Reaction conditions			
8E	-H	2-Cl	6-Cl	B	DABCO	36 %	X	R1		Solv	catalyst	yield	
9E	-H	3-Cl	5-Cl	B	DABCO	40 %	13E	2-piridyl	-COOEt	A	DABCO	48 %	
10E	-(CH ₂) ₂ COOEt	2-Cl	-H	B	DMAP	8 %	13N	2-piridyl	-CN	A	DABCO	70 %	
11E	-(CH ₂) ₂ COOEt	2-Cl	4-Cl	B	DMAP	16 %	14N	2-naftalenyl	-CN	D	DABCO	72 %	
12E	-(CH ₂) ₂ COOEt	2-Cl	6-Cl	B	DMAP	11 %	15E	cyclohexyl	-COOEt	C	DABCO	33 %	
							16E	methyl	-COOEt	B	DABCO	21 %	

Tab. 2 A = dioxane / H₂O (1/1); B = CH₃CN / H₂O (9/1); C = formamide; D = THF / MeOH / H₂O (1/1/2)

Biological results



(a) Cytotoxicity

Immortalized human tubular epithelial cells were exposed to increasing compound concentrations (0.1-100 μM). After 72 h cell viability was evaluated by MTT assay. Data are means ± S.E.M. of at least three independent experiments run in quadruplicate.

(b) Pyroptotic cell death

PMA-differentiated THP-1 cells were stimulated with LPS. Cells were treated with vehicle alone (V), parthenolide (P) or synthesized compounds (10 μM; 1 h), then pulsed with ATP in serum-free medium. The culture supernatants were collected and assayed for LDH activity. Data are means ± S.E.M. of at least three independent experiments run in triplicate.

➤ Preliminary data identify a number of compounds able to inhibit **pyroptotic cell death** which is recognized to be related to **NALP3 activation**.

➤ Compounds **4E, 8E, 9E, 16E** showed a better profile with respect to parthenolide, used as reference compound.

References

1) D. De Nardo et al. *Trends Immunol.* **2011**, *32*(8), 373-379. 2) B. K. Davis et al. *Annu. Rev. Immunol.* **2011**, *29*, 707-735. 3) S. Amslinger *ChemMedChem* **2010**, *5*, 351-356.